Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?

Sarcoidosis, an enigmatic disease with unknown etiology, is characterized by inflammation and the potential involvement of various organs, predominantly the lungs and intrathoracic lymph nodes. Non-caseating granulomas can resolve spontaneously in approximately 60% of cases within 2–3 years. However...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Karol Bączek, Wojciech Jerzy Piotrowski
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	sarcoidosis fibrosis antifibrotic agent pirfenidone nintedanib granuloma
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1445923/full

Similar Items

Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
by: Hironao Hozumi, et al.
Published: (2024-07-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry
by: Cathryn T. Lee, et al.
Published: (2024-06-01)

The Role of Antifibrotic Therapy in Pulmonary Fibrosis and Lung Cancer: A Multicenter Retrospective Analysis
by: Francesco Rocco Bertuccio, et al.
Published: (2025-09-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
by: Vito D’Agnano, et al.
Published: (2024-02-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks
by: Hsin-Yi Wang, et al.
Published: (2024-04-01)

Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study
by: Francesca Lalla, et al.
Published: (2025-10-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
by: Carlo Albera, et al.
Published: (2021-09-01)

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
by: Fabio Perrotta, et al.
Published: (2024-06-01)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
by: Stefano Levra, et al.
Published: (2022-12-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction
by: Pasquale Tondo, et al.
Published: (2025-01-01)

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
by: Shih-Lung Cheng, et al.
Published: (2022-09-01)

Lung Fibrosis after COVID-19: Treatment Prospects
by: Evgeny Bazdyrev, et al.
Published: (2021-08-01)

Pulmonary fibrosis complicated by lung cancer: bibliometric analysis from 2004 to 2024 - research status, trends and future directions
by: Boyang Li, et al.
Published: (2025-04-01)

Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
by: Yasuhiro Kondoh, et al.
Published: (2025-05-01)

Design, Synthesis and Antifibrotic Activities of Carbohydrate- Modified 1-(Substituted aryl)-5-trifluoromethyl-2(1H) Pyridones
by: Lijian Tao, et al.
Published: (2012-01-01)

Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up
by: Galina L. Ignatova, et al.
Published: (2022-09-01)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
by: Timothy M. Dempsey, et al.
Published: (2022-01-01)

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
by: Aahd Kubbara, et al.
Published: (2023-08-01)

Pulmonary fibrosis: New horizons and clinical solutions: A review II Expert Council “Idiopathic pulmonary fibrosis and progressive pulmonary fibroses. Real Practice” Symposium Review October 26, 2024, Sochi, Russia
by: Sergey N. Avdeev, et al.
Published: (2025-01-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024-06-01)

Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis
by: Chiao-Yin Sun, et al.
Published: (2025-01-01)

The Role of Nintedanib in the Treatment of Progressive Pulmonary Fibrosis of Autoimmune-Related Interstitial Lung Disease
by: Aulia Rahman Ardan, et al.
Published: (2023-11-01)

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
by: Kuo-An Chu, et al.
Published: (2020-11-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
by: A. V. Teteneva, et al.
Published: (2021-10-01)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
by: Menglin He, et al.
Published: (2024-02-01)

Effect of pirfenidone on tendon healing
by: Yasemin Aydinli, et al.
Published: (2023-01-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

The Management of Patients With Idiopathic Pulmonary Fibrosis
by: Paolo Spagnolo, et al.
Published: (2018-07-01)